Employing next-generation Inhibitor Removal Technology and improved sample disruption, the kit boosts the well-known performance of PowerSoil kits in isolating microbial DNA from soils
Germantown, Maryland, and Hilden, Germany, May 23, 2018 – QIAGEN today announced the worldwide launch of the new DNeasy PowerSoil Pro Kit, the next generation of sample technology for the extraction of fungal and bacterial DNA from a range of soil samples.
The new DNeasy PowerSoil Pro Kits featuring a streamlined version of QIAGEN’s proprietary Inhibitor Removal Technology (IRT) and a redesigned bead tube and lysis chemistry for the disruption of difficult soil samples. The DNeasy PowerSoil Pro Kits have demonstrated that they outperform the original PowerSoil technology and can generate microbial DNA isolates of even higher quality in even less time. Soil samples are challenging for molecular analyses used in microbiome research because they commonly carry substances that inhibit current methods, such as PCR and next-generation sequencing. The improved IRT and optimized chemistry of the DNeasy PowerSoil Pro Kit eliminates these inhibitors from soil and environmental samples, delivering high yields of pure microbial DNA that can be used directly in downstream applications. Furthermore, analysis of the isolated DNA reveals an accurate representation of the microbial diversity present in a sample, as measured by the total number of operational taxonomic units detected by 16S rRNA gene sequencing.
“Microbiome research is an exciting investigative area that is exponentially expanding our understanding of the microbial world,” explained Dominic O’Neil, Director of Microbiome Product Development at QIAGEN. “Scientists are uncovering symbiotic relationships that have the potential to drive improvements in crop productivity, assist environmental remediation, boost ecosystem services, or cure health conditions that we are just beginning to understand. The key to these improvements in life lies in notoriously difficult sample types, like soils. QIAGEN already offers market-leading solutions for DNA purification from such tough matrices but we continually strive to improve performance and streamline workflows. Coupled with other QIAGEN kits and instruments, we are empowering innovation in microbiome research – from Sample to Insight – by emphasizing high-quality analytes that truly represent the composition and abundance of microbial communities in samples and are ready to be used in sensitive analyses.”
Benefits of the DNeasy PowerSoil Pro Kits at a glance
- Efficient lysis of bacteria and fungi in all soil types, including compost, clay and top soil
- Up to 8-fold higher yields of DNA compared to alternative methods
- Recovery of inhibitor-free DNA ready for direct use in NGS applications
- Unbiased results, with higher alpha diversity in sequencing compared to other methods
- Sample processing can be automated on the QIAcube
The DNeasy PowerSoil Pro Kit is available now.
QIAGEN’s Leadership in Microbiome Research
As an industry pioneer of research solutions for sample preparation, in-depth molecular analyses and data interpretation, QIAGEN is a renowned supporter of microbiome research initiatives worldwide. Products from the microbiome portfolio are currently used and recommended by international consortia like the Human Microbiome Project, the Earth Microbiome Project and the MetaSUB Consortium.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2018, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).